Back to News
Market Impact: 0.3
AbbVie Reports 35.8% Endoscopic Remission With Subcutaneous Skyrizi In Crohn's Trial
Source: Nasdaq
Healthcare & Biotech
AbbVie presented new Phase 3 AFFIRM trial data for subcutaneous Skyrizi in adults with active Crohn’s disease, reporting endoscopic remission and ulcer-free endoscopy outcomes. The report provides no numerical results or further details on the outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ABBV0.65
More News
- Cue Biopharma VP Meluzio sells $32,089 in Cue stock for tax
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Top biotechnology stock pick from Guggenheim
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Needham raises Starling Oncology stock price target on growth outlook
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital IQ Alternatives for Research and Deal Work
- Research Workflows, Report Format Selection, and Interactive Synthesis